LTFS
RLMD icon

Ladenburg Thalmann Financial Services’s Relmada Therapeutics RLMD Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$7K Buy
+175
New +$5.32K ﹤0.01% 4648

Other funds holding RLMD

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ladenburg Thalmann Financial Services's RLMD Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in Relmada Therapeutics (RLMD) in Q4 2019: 175 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #4648 among its holdings.

45 funds tracked by Wall St. Rank hold RLMD as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 175 shares of Relmada Therapeutics worth $7K as of Q4 2019.
  • Relmada Therapeutics was a new Ladenburg Thalmann Financial Services position in Q4 2019.
  • Relmada Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4648 holding.
  • 45 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.